TiumBio
TiumBio has 1 licensing announcement in this dataset, dated 2022-08-08.
- Country / operating region
- South Korea
- Ticker
- 321550.KQ
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.tiumbio.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| TU2670 | GnRH | small molecule | 查無 | 2022-08-08 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| TU2670 | 查無 | — | 查無 | 查無 | 查無 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2022-08-08 | Hansoh Pharma (Hansoh Shanghai and Jiangsu Hansoh licensees) | TU2670 | USD 4.5m | 查無 | ≤ USD 164m | 查無 | Technology transfer payment USD 1.5m |
| Counterparty | Territory | Royalties |
|---|---|---|
| Hansoh Pharma (Hansoh Shanghai and Jiangsu Hansoh licensees) | Mainland China, Hong Kong, Macau and Taiwan | Tiered royalties on future net product sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無